-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dual antiplatelet therapy (DAPT) is a key strategy for early treatment of minor non-myocardial infarction ischemic stroke and transient ischemic attack (TIA)
Stroke blood vessel
In an exploratory subgroup analysis of the THALES trial, Wang Yongjun of Capital Medical University and others described the effectiveness of DAPT with ticagrelor plus aspirin in patients with acute ischemic stroke with a baseline NIHSS score of 4 or 5 in the first 30 days And safety
Describe the effectiveness and safety of DAPT with ticagrelor plus aspirin in patients with acute ischemic stroke with a baseline NIHSS score of 4 or 5 in the first 30 days
Patients took ticagrelor (180 mg loading dose on day 1 and 90 mg twice daily on days 2 to 30) or placebo within 24 hours of the onset of symptoms
Main clinical outcome: The main outcome is the time to stroke or death within 30 days
Among patients with moderate stroke, 8 patients (0.
In this large-scale study, it was found that compared with patients with less severe ischemic stroke, patients with moderate ischemic stroke benefited from ticagrelor plus aspirin and aspirin alone , while intracranial hemorrhage or other There is no further increase in the risk of serious bleeding events
Compared with patients with less severe ischemic stroke, patients with moderate ischemic stroke benefit from ticagrelor plus aspirin and aspirin alone .
Leave a message here